Skip to content

The Ellipta® in asthma and chronic obstructive pulmonary disease: device characteristics and patient acceptability

Research output: Contribution to journalArticle

Asthma and chronic obstructive pulmonary disease are primarily treated with inhaled medication, but delivery of that medication to its site of action is problematic; patients’ ability to use inhalers will affect therapeutic response. Multiple inhaler devices are available but they are variably easy to use with consequent effects on compliance, intentional or otherwise. The Ellipta® device is a novel blister strip dry powder inhaler with medium resistance and a consistent delivered dose across a range of inspiratory flow rates. The Ellipta has proven easy to use and is preferred by patients across several evaluations and compared with other inhaler devices. The Ellipta is used to administer multiple inhaled medications, all in single daily-dose regimens, making it ideal for patients who struggle with complex inhaled therapy regimens.
Original languageEnglish
Pages (from-to)169-176
JournalTherapeutic Delivery
Volume9
Issue number3
Early online date9 Feb 2018
DOIs
Publication statusPublished - Feb 2018

Documents

  • The Ellipta in asthma

    Rights statement: Thomas L. Jones, Daniel M. Neville & Anoop J. Chauhan (2018). 'The Ellipta® in asthma and chronic obstructive pulmonary disease: device characteristics and patient acceptability'. Therapeutic Delivery, 9(3), pp. 169-176. DOI: 10.4155/tde-2017-0103. © Newlands Press. All rights reserved.

    Accepted author manuscript (Post-print), 431 KB, PDF document

Related information

Relations Get citation (various referencing formats)

ID: 8871005